Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Huvudupphovsman: | Paul, Pulock |
---|---|
Övriga upphovsmän: | Azam,Faruque |
Materialtyp: | Lärdomsprov |
Språk: | English |
Publicerad: |
Brac University
2024
|
Ämnen: | |
Länkar: | http://hdl.handle.net/10361/23954 |
Liknande verk
-
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
av: Rahman, Tasnim
Publicerad: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
av: Hoque, Ismoth Ara
Publicerad: (2024) -
Pooled analysis of response rate and overall survival of Tyrosine Kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
av: Karim, Samia Binte
Publicerad: (2024) -
Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
av: Flora, Sanzida Alam
Publicerad: (2024) -
A review on targeted therapies for lung cancer
av: Ashraf, Anushey
Publicerad: (2023)